Edgar Filing: XCYTE THERAPIES INC - Form 4

XCYTE TH Form 4	ERAPIES INC											
February 03	, 2006											
FORM	14									OMB APPROVAL		
	UNITED	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							N OMB Numb	er: 323	5-0287	
Check th if no lon subject t Section Form 4 d	ger STATEN 16.								F Estima burder	Expires: January 31, 2005 Estimated average burden hours per response 0.5		
Form 5 obligation may con <i>See</i> Instr 1(b).	tinue. Section 17(Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section										
(Print or Type	Responses)											
MARXE AUSTIN W & Syr				r Name an o E THERA				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
			3. Date of Earliest Transaction (Month/Day/Year)					DirectorX 10% Owner				
	AL SITUATION 7 MADISON AV 0		02/01/2	006				Officer (g below)	ive title	_ Other (specif w)	у	
				endment, Date Original onth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
NEW YOR	K, NY 10022									Ding Person Dine Reporting		
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Secu	rities A	cquired, Disposed	l of, or Bend	eficially Own	ed	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	ar) Execution Date, if any		3. 4. Securities Acquired Transactior(A) or Disposed of Code (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or				SecuritiesOwBeneficiallyFoOwnedDirFollowingorReported(I)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature Indirect Beneficial Ownershij (Instr. 4)	1	
Common Stock	02/01/2006			Code V P	Amount 1,010 (1)	(D) A	Price \$ 0.69 (1)	4,289,098 <u>(1)</u>	I <u>(1)</u>	By Limi Partners		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title (Derivati Security (Instr. 3)	ve Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Rep	orting C	wners									
	Reporting	g Owner Name / Add	ress	Director	Relatio 10% Own	-					
MARX	E AUSTIN V	V & GREENHOU	SE DAVID M	Director	1070 OWI	er Onicer	ould				

Х

MARXE AUSTIN W & GREENHOUSE DAVID M C/O SPECIAL SITUATIONS FUNDS 527 MADISON AVENUE, SUITE 2600 NEW YORK, NY 10022

Signatures

Austin W. Marxe 02/03/2006 **Signature of Date Reporting Person David M. Greenhouse 02/03/2006 **Signature of Date Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This is a joint filing by Austin W. Marxe (Marxe) and David M. Greenhouse (Greenhouse). They share voting and investment control over all securities owned by Special Situations Fund III QP, L.P. (QP), Special Situations Cayman Fund, L.P. (Cayman) and Special

(1) Situations Life Sciences Fund, L.P. (LS), respectively. 2,952,923 shares of Common Stock are held by QP, 857,036 shares of Common Stock are held by Cayman and 479,139 shares of Common Stock are held by LS. The interest of Marxe and Greenhouse in the shares of Common Stock owned by QP, Cayman and LS is limited to the extent of his pecuniary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Edgar Filing: XCYTE THERAPIES INC - Form 4